From the Cochrane Library: Interventions for Necrotizing Soft Tissue Infections in Adults


 UNSTRUCTURED
 Summary for the Cochrane review Interventions for necrotizing soft tissue infections in adults


Management entails early surgical debridement coupled with empiric broad-spectrum intravenous antibiotics against both aerobic and anaerobic organisms in addition to intensive care support. Tissue hypoxia and necrosis induced by NSTIs limit the efficacy of systemic antibiotics, rendering surgical debridement the mainstay treatment [1].
A Cochrane review [1] investigated available interventions for NSTIs. The inclusion criteria specified randomized controlled trials of medical or surgical interventions in hospital settings for adults with NSTIs. Adjunctive hyperbaric oxygen therapy was addressed in a prior Cochrane review [2]. The primary outcome measures were mortality within 30 days and occurrence of serious adverse events, whereas the secondary outcomes were survival time as well as long-term morbidity assessed via the Functional Impairment Scale [1].
The authors identified 3 trials comprising 197 participants (n=117, 62% men) with a mean age of 55 years. In all trials, patients received the standard of care (ie, surgical debridement, empiric antibiotics, and intensive care support). The used empiric antibiotics were vancomycin, clindamycin, ciprofloxacin, and piperacillin-tazobactam [1]. One trial compared 2 antibiotic treatments, moxifloxacin 400 mg once daily and amoxicillin-clavulanate 3 g three times daily for at least 3 days, followed by 1.5 g three times daily [3]. Another trial evaluated the novel drug AB103, studied also for sepsis, which impairs T-cell activation by blocking the binding of superantigen exotoxins to the CD28 receptor on T-helper1 lymphocytes [4]. Two doses (0.5 mg/kg and 0.25 mg/kg) were investigated against the placebo. The third trial assessed intravenous immunoglobulin at a dose of 25 g/day, given for 3 consecutive days, versus a placebo [5].
In all trials, no difference was detected between groups regarding the primary outcome measures. The quality of evidence was assessed as low to very low; this implies uncertainty in these results. Adverse events, secondary outcomes, and median survival times are summarized in Table  1. None of the trials assessed long-term morbidity as defined in the review protocol [1]. The quality of the evidence was negatively impacted by attrition bias, indirectness due to the lack of a definition of NSTIs, small sample size, and underpowered analysis. The lack of high-quality evidence for this serious condition necessitates the need for larger, well-designed studies. A recent randomized controlled trial evaluated the efficacy of AB103 0.5 mg/kg versus placebo when administered within 6 hours of NSTI diagnosis [6]. No significant improvement was found in the primary composite endpoint (28-day mortality, number of debridements, amputations after the first operation, and resolution of organ dysfunction) in intention to treat whereas there was in the per-protocol population [6]. Given the rarity of NSTIs and their complex diagnosis and management, prospective registries are encouraged to provide evidence for effective therapeutic approaches to improve morbidity and mortality.

Conflicts of Interest
BLA has served as a research investigator and/or scientific advisor to AbbVie and Skin Research Institute, LLC.

Editorial notice
The views expressed in this paper are those of the authors and in no way represent the Cochrane Library or Wiley. This article is based on a Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2018, Issue 5, DOI:10.1002/14651858.CD011680.pub2 (see www.cochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.